Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07132307

Reducing Obstructive Sleep Apnea After Hypoglossal Nerve Stimulation Through Mandibular Advancement

The purpose of this study is to evaluate the effectiveness, feasibility, and safety of mandibular advancement devices (MAD) for treating severe obstructive sleep apnea (OSA) in patients who are CPAP intolerant and have failed hypoglossal nerve stimulation (HGNS).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Obstructive Sleep Apnea Apnea Dyssomnias Nervous System Diseases Respiration Disorders Respiratory Tract Diseases Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep Disorders, Intrinsic Sleep Wake Disorders

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location status: Recruiting

Location contact

Sara Kukuljan, BS, RN

CONTACT

[email protected]

314-362-7563

About this study

ROHMA is a pilot/single intervention study aiming to evaluate effectiveness of a mandibular advancement device (MAD) for treating moderate to severe obstructive sleep apnea (OSA) in patients who have failed hypoglossal nerve stimulation therapy (HGNS). Individuals who received a HGNS therapy at Washington University from April 4 2019 to October 20 2024, or were enrolled in a prior study (HRPO #: 202309014) will be recruited for the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Ability to read, write, speak, and understand English.
  • Failure of hypoglossal nerve stimulation (HGNS) therapy, defined as intolerance to HGNS or insufficient AHI reduction based on modified Sher criteria while using HGNS.
  • Ability to insert and remove the mandibular advancement device (MAD) independently.
  • Ability to complete all study assessments and evaluations, including home sleep apnea tests (HSAT).
  • Ability to abstain from any other treatment for obstructive sleep apnea (OSA) during the entire study duration.
  • Access to an internet-connected device (phone, tablet, or laptop) with a camera.

Exclusion criteria

  • Age over 70 years.
  • Inability to use a mandibular advancement device (MAD), defined as having fewer than 9 healthy teeth per dental arch.
  • Prior intolerance to MAD therapy.
  • Previous participation in a trial involving the use of oral appliances.
  • Chronic nasal obstruction.
  • Dependence on or frequent use of medications that alter consciousness, respiration, or alertness.
  • Insomnia and/or use of medications to treat insomnia.
  • Sleep disorders such as narcolepsy, insomnia, restless leg syndrome, or other disorders affecting sleep, and/or use of medications to treat such disorders.
  • Substance abuse.
  • Unstable psychiatric disorders.
  • Current use of a GLP-1 receptor agonist (e.g., Zepbound, Wegovy, Ozempic, Mounjaro) with ongoing, active weight loss at the time of enrollment, or recent dose escalation within the prior 8 weeks.

Treatment and study plan

Mandibular advancement device (MAD)

Device

The intervention in this study involves fitting and using a mandibular advancement device (MAD), specifically the ProSomnus Sleep Device, to treat moderate to severe obstructive sleep apnea (OSA) in patients who are intolerant to CPAP and have failed hypoglossal nerve stimulation (HGNS) therapy.

Other names: ProSomnus Sleep Device.

Primary outcomes

  1. Proportion of responders

    Time frame: through study completion on average 8 weeks

    The proportion of responders will be defined as number of participants with more than a 50% reduction in apnea-hypopnea index (AHI) and a final AHI less than 15 (modified Sher criteria) after treatment compared to baseline, divided by the total number of participants treated with mandibular advancement device.

    The AHI is a standardized index used to diagnose and determine the severity of sleep apnea. AHI will be obtained from a home sleep apnea test completed by the participants and reviewed by a trained sleep neurologist.

Secondary outcomes

  1. Magnitude of change in apnea-hypopnea index (AHI).

    Time frame: through study completion on average 8 weeks

    The magnitude of change in apnea-hypopnea index (AHI) refers to the difference in AHI values measured before and after using the mandibular advancement device (MAD).

  2. Change in Oxygen desaturation index (ODI)

    Time frame: through study completion on average 8 weeks

    The ODI is an index used to measure the degree of oxygen desaturation during sleep. The ODI will be obtained from the sleep study results by a trained sleep neurologist.

    Change in ODI will be calculated as the difference ODI pre and post treatment sleep studies.

  3. Change in the time spent below oxygen saturation 90%

    Time frame: through study completion on average 8 weeks

    The time spent below oxygen saturation 90% difference will be defined as the difference of the length of time where participants have an arterial saturation of oxygen below 90% during pre- and post- treatment sleep study.

  4. Changes in the mean arterial oxygen saturation (SaO2)

    Time frame: through study completion on average 8 weeks

    The changes in arterial oxygen saturation (SaO2) will be defined as the difference in the mean arterial oxygen saturation recorded during pre- and post- treatment sleep studies.

  5. Adherence to MAD use

    Time frame: through study completion on average 8 weeks

    Adherence is defined as using the MAD for at least 4 hours per night on at least 5 out of 7 nights during the entire intervention period.

    The proportion of participants meeting this adherence criterion is calculated and reported to assess feasibility and compliance with the treatment.

  6. Change in Epworth Sleepiness Scale (ESS)

    Time frame: through study completion on average 8 weeks

    The Epworth Sleepiness Scale (ESS) is measured by asking participants to rate their likelihood of falling asleep in eight different everyday situations on a scale from 1 (least likely) to 7 (most likely).

    The total ESS score reflects the level of daytime sleepiness, with higher scores indicating greater sleepiness.

    Change in the Epworth Sleepiness Scale (ESS) is assessed by comparing participants' ESS scores before starting mandibular advancement device (MAD) therapy (baseline) with their scores after the intervention period.

  7. Epworth Sleepiness Scale (ESS) improvement

    Time frame: through study completion on average 8 weeks

    The Epworth Sleepiness Scale (ESS) is measured by asking participants to rate their likelihood of falling asleep in eight different everyday situations on a scale from 1 (least likely) to 7 (most likely).

    The total ESS score reflects the level of daytime sleepiness, with higher scores indicating greater sleepiness.

    Change in the Epworth Sleepiness Scale (ESS) is assessed by comparing participants' ESS scores before starting mandibular advancement device (MAD) therapy (baseline) with their scores after the intervention period.

    The proportion of participants with improved ESS will be calculated as number of participants whose ESS score changes exceed the minimal clinically important difference (MCID) of 2.4 points divided by the total number of participants.

  8. Symptoms of Nocturnal Obstruction and Related Events (SNORE-25)

    Time frame: through study completion on average 8 weeks

    The Symptoms of Nocturnal Obstruction and Related Events (SNORE-25) is a validated 25-item questionnaire used to assess sleep-disorder related morbidity by capturing the frequency and severity of symptoms associated with obstructive sleep apnea. The total score ranges from 0 to 5, with higher scores indicating a greater health burden related to sleep-disordered breathing.

    Change in the Symptoms of Nocturnal Obstruction and Related Events (SNORE-25) scale is assessed by comparing participants' SNORE-25 scores before starting mandibular advancement device (MAD) therapy with their scores after completing the intervention period.

  9. Clinical Global Impression of Improvement (CGI-I) Scale

    Time frame: through study completion on average 8 weeks

    The Clinical Global Impression of Improvement (CGI-I) scale is a validated, widely used tool that asks participants to rate their overall response to a treatment-in this case, mandibular advancement device (MAD) therapy for obstructive sleep apnea.

    Participants select one of seven response options: Very Much Improved, Much Improved, Minimally Improved, No Change, Minimally Worse, Much Worse, or Very Much Worse. The proportion of participants reporting improvement is defined as those who choose "Much Improved" or "Very Much Improved" divided by the total number of participants completing the study.

Study contacts

Contact information is provided by the study sponsor or research team.

Jay F Piccirillo, MD

CONTACT

[email protected]

314-362-8641

Sara Kukuljan

CONTACT

[email protected]

314-362-7653

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Official study title

Reducing Obstructive Sleep Apnea After Hypoglossal Nerve Stimulation Through

Acronym: ROHMA

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Aug 20, 2025
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.